share_log

Vertex Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital World Investors(10.0%)

SEC announcement ·  Apr 11 00:17
Summary by Futu AI
Capital World Investors (CWI), a division of Capital Research and Management Company, has filed an amendment with the United States Securities and Exchange Commission (SEC) on April 10, 2024, indicating that they hold a 10% ownership stake in Vertex Pharmaceuticals Inc. The Schedule 13G filing, specifically under Rule 13d-1(b), shows that CWI possesses sole voting power over 25,811,092 shares and sole dispositive power over 25,902,938 shares of Vertex Pharmaceuticals' common stock. This represents a significant position in the company, with CWI being deemed the beneficial owner of these shares. The filing was made to comply with SEC regulations that require disclosure when certain thresholds of ownership in a publicly-traded company are reached or exceeded. The address for Vertex Pharmaceuticals is listed as 50 Northern Avenue, Boston, MA 02210, and the CUSIP number for the common stock is 92532F100. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vertex Pharmaceuticals.
Capital World Investors (CWI), a division of Capital Research and Management Company, has filed an amendment with the United States Securities and Exchange Commission (SEC) on April 10, 2024, indicating that they hold a 10% ownership stake in Vertex Pharmaceuticals Inc. The Schedule 13G filing, specifically under Rule 13d-1(b), shows that CWI possesses sole voting power over 25,811,092 shares and sole dispositive power over 25,902,938 shares of Vertex Pharmaceuticals' common stock. This represents a significant position in the company, with CWI being deemed the beneficial owner of these shares. The filing was made to comply with SEC regulations that require disclosure when certain thresholds of ownership in a publicly-traded company are reached or exceeded. The address for Vertex Pharmaceuticals is listed as 50 Northern Avenue, Boston, MA 02210, and the CUSIP number for the common stock is 92532F100. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vertex Pharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.